|
|
Prepublished online as a Blood First Edition Paper on April 10, 2003; DOI 10.1182/blood-2002-11-3507.
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2003, Vol. 102, No. 3, pp. 1019-1027
NEOPLASIA
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
Bei Zheng,
Paolo Fiumara,
Yang V. Li,
Georgios Georgakis,
Virginia Snell,
Mamoun Younes,
Jean Nicolas Vauthey,
Antonino Carbone, and
Anas Younes
From the Departments of Lymphoma/Myeloma and Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston; Department of Pathology, Baylor College of Medicine, Houston, TX; and National Institute of Cancer, Aviano, Italy
The mitogen-activated protein kinase (MAPK) (also called extracellular signal–regulated kinase [ERK]) pathway has been implicated in malignant transformation and in the regulation of cellular growth and proliferation of several tumor types, but its expression and function in Hodgkin disease (HD) are unknown. We report here that the active phosphorylated form of MAPK/ERK is aberrantly expressed in cultured and primary HD cells. Inhibition of the upstream MAPK kinase (also called MEK) by the small molecule UO126 inhibited the phosphorylation of ERK and demonstrated a dose- and time-dependent antiproliferative activity in HD cell lines. UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia–1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis. Furthermore, UO126 potentiated the activity of apoliprotein 2/tumor necrosis factor–related apoptosis-inducing ligand (APO2L/TRAIL) and chemotherapy-induced cell death. Activation of CD30, CD40, and receptor activator of nuclear kappa (RANK) receptors in HD cells by their respective ligands increased ERK phosphorylation above the basal level and promoted HD cell survival. UO126 inhibited basal and ligand-induced ERK phosphorylation, and inhibited ligand-induced cell survival of HD cell lines. These findings provide a proof-of-principle that inhibition of the MEK/ERK pathway may have therapeutic value in HD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Buglio, G. V. Georgakis, S. Hanabuchi, K. Arima, N. M. Khaskhely, Y.-J. Liu, and A. Younes
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
Blood,
August 15, 2008;
112(4):
1424 - 1433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Homig-Holzel, C. Hojer, J. Rastelli, S. Casola, L. J. Strobl, W. Muller, L. Quintanilla-Martinez, A. Gewies, J. Ruland, K. Rajewsky, et al.
Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-{kappa}B pathway and promotes lymphomagenesis
J. Exp. Med.,
June 9, 2008;
205(6):
1317 - 1329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Kapatai and P Murray
Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1342 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Wright, J. M. Rumble, and C. S. Duckett
CD30 Activates Both the Canonical and Alternative NF-{kappa}B Pathways in Anaplastic Large Cell Lymphoma Cells
J. Biol. Chem.,
April 6, 2007;
282(14):
10252 - 10262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagel, C. Burek, L. Venturini, M. Scherr, H. Quentmeier, C. Meyer, A. Rosenwald, H. G. Drexler, and R. A. F. MacLeod
Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1
Blood,
April 1, 2007;
109(7):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Krysov, T. F. Rowley, and A. Al-Shamkhani
Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells
Mol. Cancer Ther.,
February 1, 2007;
6(2):
703 - 711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chiu, W. Xu, B. He, S. R. Dillon, J. A. Gross, E. Sievers, X. Qiao, P. Santini, E. Hyjek, J.-w. Lee, et al.
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
Blood,
January 15, 2007;
109(2):
729 - 739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hollmann, T. Owens, J. Nalbantoglu, T. J. Hudson, and R. Sladek
Constitutive Activation of Extracellular Signal-Regulated Kinase Predisposes Diffuse Large B-Cell Lymphoma Cell Lines to CD40-Mediated Cell Death.
Cancer Res.,
April 1, 2006;
66(7):
3550 - 3557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Himes, D. P. Sester, T. Ravasi, S. L. Cronau, T. Sasmono, and D. A. Hume
The JNK Are Important for Development and Survival of Macrophages
J. Immunol.,
February 15, 2006;
176(4):
2219 - 2228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. V. Georgakis, Y. Li, G. Z. Rassidakis, H. Martinez-Valdez, L. J. Medeiros, and A. Younes
Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal-Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death
Clin. Cancer Res.,
January 15, 2006;
12(2):
584 - 590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Brown and N. R. Kamal
p-p70S6K (Thr 389) Expression in Nodular Sclerosing Hodgkin's Disease as Evidence for Receptor Tyrosine Kinase Signaling
Ann. Clin. Lab. Sci.,
October 1, 2005;
35(4):
413 - 414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Re, R. Kuppers, and V. Diehl
Molecular Pathogenesis of Hodgkin's Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6379 - 6386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Watanabe, M. Sasaki, K. Itoh, M. Higashihara, K. Umezawa, M. E. Kadin, L. J. Abraham, T. Watanabe, and R. Horie
JunB Induced by Constitutive CD30-Extracellular Signal-Regulated Kinase 1/2 Mitogen-Activated Protein Kinase Signaling Activates the CD30 Promoter in Anaplastic Large Cell Lymphoma and Reed-Sternberg Cells of Hodgkin Lymphoma
Cancer Res.,
September 1, 2005;
65(17):
7628 - 7634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Re, R. K. Thomas, K. Behringer, and V. Diehl
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Blood,
June 15, 2005;
105(12):
4553 - 4560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Mikhalap, L. M. Shlapatska, O. V. Yurchenko, M. Y. Yurchenko, G. G. Berdova, K. E. Nichols, E. A. Clark, and S. P. Sidorenko
The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells
Blood,
December 15, 2004;
104(13):
4063 - 4070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Relic, V. Benoit, N. Franchimont, C. Ribbens, M.-J. Kaiser, P. Gillet, M.-P. Merville, V. Bours, and M. G. Malaise
15-Deoxy-{Delta}12,14-prostaglandin J2 Inhibits Bay 11-7085-induced Sustained Extracellular Signal-regulated Kinase Phosphorylation and Apoptosis in Human Articular Chondrocytes and Synovial Fibroblasts
J. Biol. Chem.,
May 21, 2004;
279(21):
22399 - 22403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Zheng, G. V. Georgakis, Y. Li, A. Bharti, D. McConkey, B. B. Aggarwal, and A. Younes
Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-{kappa}B Mutations or Activation of the CD30, CD40, and RANK Receptors
Clin. Cancer Res.,
May 1, 2004;
10(9):
3207 - 3215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
